BMC Public Health (Feb 2024)

Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States

  • Mondher Toumi,
  • Jack Wallace,
  • Chari Cohen,
  • Chris Marshall,
  • Helen Kitchen,
  • Jake Macey,
  • Hannah Pegram,
  • Ashley F. Slagle,
  • Robert G. Gish,
  • Qin Ning,
  • Hiroshi Yatsuhashi,
  • Markus Cornberg,
  • Maurizia Brunetto,
  • Florian van Bömmel,
  • Qing Xie,
  • Dee Lee,
  • Noriyuki Habuka,
  • Urbano Sbarigia,
  • Maria Beumont-Mauviel,
  • Angelina Villasis Keever,
  • Yasushi Takahashi,
  • Yiwei Lu,
  • Ao Liu,
  • Qiaoqiao Chen,
  • Tetsuro Ito,
  • Olaf Radunz,
  • Anna Puggina,
  • Gudrun Hilgard,
  • Eric K.H. Chan,
  • Su Wang

DOI
https://doi.org/10.1186/s12889-023-17263-6
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background People with chronic hepatitis B (CHB) commonly experience social and self-stigma. This study sought to understand the impacts of CHB-related stigma and a functional cure on stigma. Methods Adults with CHB with a wide range of age and education were recruited from 5 countries and participated in 90-minute qualitative, semi-structured interviews to explore concepts related to CHB-associated stigma and its impact. Participants answered open-ended concept-elicitation questions regarding their experience of social and self-stigma, and the potential impact of reduced CHB-related stigma. Results Sixty-three participants aged 25 to 71 years (15 from the United States and 12 each from China, Germany, Italy, and Japan) reported emotional, lifestyle, and social impacts of living with CHB, including prejudice, marginalization, and negative relationship and work experiences. Self-stigma led to low self-esteem, concealment of CHB status, and social withdrawal. Most participants stated a functional cure for hepatitis B would reduce self-stigma. Conclusions CHB-related social and self-stigma are widely prevalent and affect many aspects of life. A functional cure for hepatitis B may reduce social and self-stigma and substantially improve the health-related quality of life of people with CHB. Incorporating stigma into guidelines along with infectivity considerations may broaden the patient groups who should receive treatment.

Keywords